Diverse Biotech, Inc., is not a “single-drug” or “single-disease” company. Diverse draws intellectual property from our own proprietary patent-pending IP repository, consisting of thousands of novel, lead molecules in the following drug classes;
Our short-term goal is to increase the value of the entire IP pipeline. By continuing downstream proof of concept. Every molecule that is proven to have increased effectiveness and every molecule licensed-out, increases the value of other molecules in the portfolio.
We expect to file for an IND for our lead molecule, DBT-30180 for first-line Glioblastoma therapy by the end of Q2 2023. The acceptance of this step by the FDA, will dramatically increase the value of the Company and open up many new licensing opportunities.
Our molecules show a high level of effectiveness and carry less downstream development risk because we start with parent-drugs that are already understood and FDA approved. We connect such drugs with specific cannabinoids, on a molecular level, to create our novel molecules. Our new molecules show better properties (including efficacy, delivery and safety) than either the parent drug, the cannabinoid or an traditional combination therapy utilizing the two drugs separately.